Skip to main navigation Skip to search Skip to main content

Advances in Biomolecular Condensates: From Disease Therapy to Synthetic Biology

  • Wenjun Xie
  • , Chaojuan Yang
  • , Mengqian Shi
  • , Luyang Zhao*
  • , Xuehai Yan*
  • , Ruirui Xing*
  • *Corresponding author for this work
  • CAS - Institute of Process Engineering
  • University of Chinese Academy of Sciences

Research output: Contribution to journalReview articlepeer-review

Abstract

Biomolecular condensates (BMCs) are membraneless organelles (MLOs) formed by liquid–liquid phase separation (LLPS) of biomolecules such as proteins and nucleic acids (NAs). They are widely present in organisms and participate in key life processes such as gene transcription regulation. Its dynamic, environmental responsiveness and selective enrichment capabilities lay the foundation for biomedical and engineering biology applications and can be used as innovative targets for new drug research and disease treatment, for building bioreactors, and for developing intelligent biomaterials as well as delivery systems. At present, the related research is converted into various frontier applications, especially providing new intervention strategies for previously undruggable targets. This paper reviews the latest breakthroughs, technical challenges, and future directions from the perspective of frontier applications.

Original languageEnglish
Article numbere202500931
JournalChemBioChem
Volume27
Issue number6
DOIs
StatePublished - 27 Mar 2026

Keywords

  • biomolecular condensate
  • drug delivery
  • liquid–liquid phase separation
  • peptide condensate
  • synthetic biology

Fingerprint

Dive into the research topics of 'Advances in Biomolecular Condensates: From Disease Therapy to Synthetic Biology'. Together they form a unique fingerprint.

Cite this